Putting the brakes on anticancer therapies: Suppression of innate immune pathways by tumor-associated myeloid cells

Trends in Molecular Medicine

Volumn 19, Issue 9, 2013, Pages 536-545

  Jinushi, Masahisa ^a   Yagita, Hideo ^b   Yoshiyama, Hironori ^a   Tahara, Hideaki ^c  

^a HOKKAIDO UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Chemoresistant niche; Danger associated molecular patterns; Immunogenic cell death; Innate immune pathways; Phagocytosis receptors; Tumor associated myeloid cells

Indexed keywords

ANTHRACYCLINE; CISPLATIN; COLONY STIMULATING FACTOR 1; DACARBAZINE; DOXORUBICIN; FLUOROURACIL; GELATINASE A; GELATINASE B; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; METHOTREXATE; OXALIPLATIN; PACLITAXEL; PATTERN RECOGNITION RECEPTOR; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; SCATTER FACTOR; STAT3 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN A;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; AUTOIMMUNITY; AUTOPHAGY; BONE MARROW CELL; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; CARCINOGENIC ACTIVITY; CARCINOGENICITY; CELL STRESS; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INNATE IMMUNITY; MACROPHAGE; MELANOMA; METASTASIS; MONOCYTE; PATTERN RECOGNITION; PHAGOCYTOSIS; PROSTATE CANCER; REGULATORY MECHANISM; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

CHEMORESISTANT NICHE; DANGER-ASSOCIATED MOLECULAR PATTERNS; IMMUNOGENIC CELL DEATH; INNATE IMMUNE PATHWAYS; PHAGOCYTOSIS RECEPTORS; TUMOR-ASSOCIATED MYELOID CELLS;

ANTINEOPLASTIC AGENTS; CELL DEATH; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNITY, INNATE; MOLECULAR TARGETED THERAPY; MYELOID CELLS; PHAGOCYTOSIS; SIGNAL TRANSDUCTION;

EID: 84883820837     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2013.06.001     Document Type: Review

References (78)

1. Meads M.B., et al. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat. Rev. Cancer 2009, 9:665-674.
2. Grivennikov S.I., et al. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
3. McMillin D.W., et al. The role of tumor-stromal interactions in modifying drug responses: challenges and opportunities. Nat. Rev. Drug Discov. 2013, 12:217-228.
4. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 2009, 9:239-252.
5. Hanahan D., Coussens L.M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012, 21:309-322.
6. Gilbert L.A., Hemann M.T. DNA damage-mediated induction of a chemoresistant niche. Cell 2010, 143:355-366.
7. Straussman R., et al. Tumor micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487:500-504.
8. Sun Y., et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat. Med. 2012, 18:1359-1368.
9. Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39-51.
10. Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 2010, 11:889-896.
11. De Palma M., Lewis C.E. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 2013, 23:277-286.
12. Kodumudi K.N., et al. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin. Cancer Res. 2010, 16:4583-4594.
13. Germano G., et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 2013, 23:249-262.
14. Qian B.Z., et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumor metastasis. Nature 2011, 475:222-225.
15. De Palma M., et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005, 8:211-226.
16. Welford A.F., et al. TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. J. Clin. Invest. 2011, 121:1969-1973.
17. Gabrilobich D.I. Coordinated regulation of myeloid cells by tumors. Nat. Rev. Immunol. 2012, 12:253-268.
18. Scarlett U.K., et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J. Exp. Med. 2012, 209:495-506.
19. Conejo-Garcia J.R., et al. Tumor-infiltrating dendritic cell precursors recruited by a β-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat. Med. 2004, 10:950-958.
20. Chiba S., et al. Tumor-infiltrating dendritic cells suppress nucleic acid-mediated innate immune responses through TIM-3-HMGB1 interactions. Nat. Immunol. 2012, 13:832-842.
21. Ma Y., et al. Antitumor chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013, 38:729-741.
22. Mundy-Bosse B.L., et al. Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Cancer Res. 2011, 71:5101-5110.
23. Bruchard M., et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat. Med. 2013, 19:57-64.
24. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 2004, 4:11-22.
25. Lin W.W., Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 2007, 117:1175-1183.
26. Lin E.Y., et al. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 2001, 193:727-740.
27. Kubota Y., et al. M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J. Exp. Med. 2009, 206:1089-1102.
28. DeNardo D.G., et al. Leukocyte complexity predicts breast cancer survival and functionality regulates response to chemotherapy. Cancer Discov. 2011, 1:54-67.
29. Karin M., Lin A. NF-κB at the crossroads of life and death. Nat. Immunol. 2002, 3:221-227.
30. Balkwill F. Tumor necrosis factor and cancer. Nat. Rev. Cancer 2009, 9:361-371.
31. Grivennikov S., et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113.
32. Shree T., et al. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev. 2011, 25:2465-2479.
33. Magee J.A., et al. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 2012, 21:283-296.
34. Iliopoulos D., et al. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL-6 secretion. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:1397-1402.
35. Reynaud D., et al. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell 2011, 20:661-673.
36. Jinushi M., et al. Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:24725-24730.
37. Mitchem J.B., et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 2013, 73:1128-1141.
38. Cary M.S., et al. Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-β pathway signaling indicates response to primary chemotherapy. Clin. Cancer Res. 2010, 16:2852-2860.
39. Naka K., et al. TGF-β-FOXO signaling maintains leukemia-initiating cells in chronic myeloid leukemia. Nature 2010, 463:676-680.
40. Langowski J.L., et al. IL-23 promotes tumor incidence and growth. Nature 2006, 442:461-465.
41. Ma Y., et al. Contribution of IL-17-producing γδ T cells to the efficacy of antitcancer chemotherapy. J. Exp. Med. 2011, 208:491-503.
42. Wei S., et al. Th17 cells have stem cell like features and promote long-term immunity. Oncoimmunology 2012, 1:516-519.
43. Nakasone E.S., et al. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 2012, 21:488-503.
44. Ebrahem Q., et al. Cross-talk between vascular endothelial growth factor and matrix metalloproteinases in the induction of neovascularization in vivo. Am. J. Pathol. 2010, 176:496-503.
45. Krysko D., et al. Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 2012, 12:860-875.
46. Kroemer G., et al. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 2012, 31:51-72.
47. Takeuchi O., Akira S. Pattern recognition receptors and inflammation. Cell 2010, 140:805-820.
48. Apetoh L., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 2007, 13:1050-1059.
49. Kim S., et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009, 457:102-106.
50. Mittal D., et al. TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO J. 2010, 29:2242-2252.
51. Cherfils-Vicini J., et al. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J. Clin. Invest. 2010, 120:1285-1297.
52. Freeman G.J., et al. TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol. Rev. 2010, 235:172-189.
53. Anderson A.C., et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science 2007, 318:1141-1143.
54. Poeck H., et al. 5'-Triphosphate-siRNA: tuning gene silencing and Rig-I activation against melanoma. Nat. Med. 2008, 14:1256-1263.
55. Kubler K., et al. Targeted activation of RNA helicase retinoic acid-inducible gene-I induces proimmunogenic apoptosis of human ovarian cancer cells. Cancer Res. 2010, 70:5293-5304.
56. Gebhardt C., et al. RAGE signaling sustains inflammation and promotes tumor development. J. Exp. Med. 2008, 205:275-285.
57. Tagcuchi A., et al. Blockade of RAGE-amphoterin signaling suppresses tumor growth and metastasis. Nature 2000, 405:354-360.
58. Ghiringhelli F., et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors. Nat. Med. 2009, 15:1170-1178.
59. Michaud M., et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011, 334:1573-1577.
60. Nagata S., et al. Autoimmunity and the clearance of dead cells. Cell 2010, 140:619-630.
61. Savill J., et al. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat. Rev. Immunol. 2002, 2:965-975.
62. Hanayama R., et al. Identification of a factor that links apoptotic cells to phagocytosis. Nature 2002, 417:182-187.
63. Jinushi M., et al. MFG-E8-mediated uptake of apoptotic cells by APCs links pro- and anti-inflammatory activities of GM-CSF. J. Clin. Invest. 2007, 117:1902-1913.
64. Jinushi M., et al. Milk fat globule EGF-8 promotes melanoma progression through coordinated Akt and twist signaling in the tumor microenvironments. Cancer Res. 2008, 68:8889-8898.
65. Jinushi M., et al. Milk-fat globule EGF-8 triggers tumor destruction through coordinated cell autonomous and immune-mediated mechanisms. J. Exp. Med. 2009, 206:1317-1326.
66. Png K.J., et al. A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature 2011, 481:190-194.
67. Rogers A.E., et al. Mer receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology. Oncogene 2012, 31:4171-4181.
68. Neyen C., et al. Macrophage scavenger receptor A promotes tumor progression in murine models of ovarian and pancreatic cancers. J. Immunol. 2013, 190:3798-3805.
69. Green D.R., et al. Immunogenic and tolerogenic cell death. Nat. Rev. Immunol. 2009, 9:353-363.
70. Gardai S.J., et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cell through transactivation of LRP on the phagocytes. Cell 2005, 123:321-334.
71. Laura S., et al. An immunosurveillance mechanism controls cancer cell ploidy. Science 2012, 337:1678-1684.
72. Obeid M., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 2007, 13:54-61.
73. Chao M.P., et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and counterbalanced by CD47. Sci. Transl. Med. 2010, 2:63ra94.
74. Chao M.P., et al. Programmed cell removal: a new obstacle in the road to developing cancer. Nat. Rev. Cancer 2011, 12:58-67.
75. Remakrishnan R., et al. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer. J. Clin. Invest. 2010, 120:1111-1124.
76. Ciampricotti M., et al. Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system. Nat. Med. 2012, 18:344-346.
77. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
78. Rubinsztein D.C., et al. Autophagy modulation as a potential therapeutic target for diverse diseases. Nat. Rev. Drug Discov. 2012, 11:709-730.